The evolving management of acute right-sided heart failure in cardiac transplant recipients
Avoidance of the clinical syndrome of acute right-sided heart failure after heart transplantation is, unfortunately, not possible. Clinical experience and the literature certainly suggest that a significant factor in the successful management of right ventricular (RV) failure is recipient selection....
Gespeichert in:
Veröffentlicht in: | Journal of the American College of Cardiology 2001-10, Vol.38 (4), p.923-931 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 931 |
---|---|
container_issue | 4 |
container_start_page | 923 |
container_title | Journal of the American College of Cardiology |
container_volume | 38 |
creator | Stobierska-Dzierzek, Bozena Awad, Hamdy Michler, Robert E |
description | Avoidance of the clinical syndrome of acute right-sided heart failure after heart transplantation is, unfortunately, not possible. Clinical experience and the literature certainly suggest that a significant factor in the successful management of right ventricular (RV) failure is recipient selection. Moreover, threshold hemodynamic values beyond which RV failure is certain to occur and heart transplantation is contraindicated do not exist. Nor are there values below which RV failure is always avoidable. Acute RV failure will remain a difficult and ever-present clinical syndrome in the transplant recipient. Goals in the treatment of this clinical problem include: 1. Preserving coronary perfusion through maintenance of systemic blood pressure. 2. Optimizing RV preload. 3. Reducing RV afterload by decreasing pulmonary vascular resistance (PVR). 4. Limiting pulmonary vasoconstriction through ventilation with high inspired oxygen concentrations (100% Fio2), increased tidal volume and optimal positive end expiratory pressure ventilation. Inhaled nitric oxide is recommended before leaving the operating room in cases where the initial therapies have had little impact. Intra-aortic balloon counterpulsation is employed in patients with impaired left ventricular (LV) function and may be of benefit in patients with RV dysfunction resulting from ischemia, preservation injury or reperfusion injury. Optimal LV function reduces RV afterload and PVR. A proactive decision regarding RV assist device implantation is made before leaving the operating room and is highly dependent upon overall hemodynamics, size and function of the ventricles as seen on transesophageal echocardiography, renal function and surgical bleeding. Only through careful preoperative planning can this life-threatening condition be managed in the postoperative period. |
doi_str_mv | 10.1016/S0735-1097(01)01486-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71220029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109701014863</els_id><sourcerecordid>71220029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-37ccb31042515505f54f6c5d759aa15522b98245c793d8b8851bc63f52317bd93</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi3UCpaPn0DlSxEcUjx2HDsnhBDQSkg9FE4cLMee7LrKx9ZOVuq_x8uuyrGnkUbPO_PqIeQc2DdgUF3_YkrIAlitLhlcMSh1VYgDsgApdSFkrT6RxT_kiByn9JsxVmmoD8kRgNRCV2xBXp9XSHEzdpswLGlvB7vEHoeJji21bp6QxrBcTUUKHj1doY0TbW3o5og0DNTZ6IN1dIp2SOvO5mBEF9Yhn0in5HNru4Rn-3lCXh7un---F08_H3_c3T4VrlR8KoRyrhHASi5zeSZbWbaVk17J2tq84bypNS-lU7XwutFaQuMq0UouQDW-FifkYnd3Hcc_M6bJ9CE57HIdHOdkFHDOGN-Ccge6OKYUsTXrGHob_xpgZmvVvFs1W2WGgXm3akTOfdk_mJse_UdqrzEDX_eATc52bbbhQvrgShAK5LbAzY7DrGMTMJrksiqHPmRtk_Fj-E-VN_jIk2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71220029</pqid></control><display><type>article</type><title>The evolving management of acute right-sided heart failure in cardiac transplant recipients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Stobierska-Dzierzek, Bozena ; Awad, Hamdy ; Michler, Robert E</creator><creatorcontrib>Stobierska-Dzierzek, Bozena ; Awad, Hamdy ; Michler, Robert E</creatorcontrib><description>Avoidance of the clinical syndrome of acute right-sided heart failure after heart transplantation is, unfortunately, not possible. Clinical experience and the literature certainly suggest that a significant factor in the successful management of right ventricular (RV) failure is recipient selection. Moreover, threshold hemodynamic values beyond which RV failure is certain to occur and heart transplantation is contraindicated do not exist. Nor are there values below which RV failure is always avoidable. Acute RV failure will remain a difficult and ever-present clinical syndrome in the transplant recipient. Goals in the treatment of this clinical problem include: 1. Preserving coronary perfusion through maintenance of systemic blood pressure. 2. Optimizing RV preload. 3. Reducing RV afterload by decreasing pulmonary vascular resistance (PVR). 4. Limiting pulmonary vasoconstriction through ventilation with high inspired oxygen concentrations (100% Fio2), increased tidal volume and optimal positive end expiratory pressure ventilation. Inhaled nitric oxide is recommended before leaving the operating room in cases where the initial therapies have had little impact. Intra-aortic balloon counterpulsation is employed in patients with impaired left ventricular (LV) function and may be of benefit in patients with RV dysfunction resulting from ischemia, preservation injury or reperfusion injury. Optimal LV function reduces RV afterload and PVR. A proactive decision regarding RV assist device implantation is made before leaving the operating room and is highly dependent upon overall hemodynamics, size and function of the ventricles as seen on transesophageal echocardiography, renal function and surgical bleeding. Only through careful preoperative planning can this life-threatening condition be managed in the postoperative period.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(01)01486-3</identifier><identifier>PMID: 11583860</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Alprostadil - therapeutic use ; Animals ; Biological and medical sciences ; Cardiotonic Agents - therapeutic use ; Epoprostenol - therapeutic use ; Heart Transplantation - adverse effects ; Heart Transplantation - physiology ; Heart-Assist Devices ; Hemodynamics ; Humans ; Hypertension, Pulmonary - etiology ; Hypertension, Pulmonary - therapy ; Medical sciences ; Milrinone - therapeutic use ; Nitric Oxide - therapeutic use ; Phosphodiesterase Inhibitors - therapeutic use ; Risk Factors ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the heart ; Vasodilator Agents - therapeutic use ; Ventricular Dysfunction, Right - drug therapy ; Ventricular Dysfunction, Right - etiology ; Ventricular Dysfunction, Right - therapy</subject><ispartof>Journal of the American College of Cardiology, 2001-10, Vol.38 (4), p.923-931</ispartof><rights>2001 American College of Cardiology</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-37ccb31042515505f54f6c5d759aa15522b98245c793d8b8851bc63f52317bd93</citedby><cites>FETCH-LOGICAL-c472t-37ccb31042515505f54f6c5d759aa15522b98245c793d8b8851bc63f52317bd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0735-1097(01)01486-3$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14137159$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11583860$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stobierska-Dzierzek, Bozena</creatorcontrib><creatorcontrib>Awad, Hamdy</creatorcontrib><creatorcontrib>Michler, Robert E</creatorcontrib><title>The evolving management of acute right-sided heart failure in cardiac transplant recipients</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>Avoidance of the clinical syndrome of acute right-sided heart failure after heart transplantation is, unfortunately, not possible. Clinical experience and the literature certainly suggest that a significant factor in the successful management of right ventricular (RV) failure is recipient selection. Moreover, threshold hemodynamic values beyond which RV failure is certain to occur and heart transplantation is contraindicated do not exist. Nor are there values below which RV failure is always avoidable. Acute RV failure will remain a difficult and ever-present clinical syndrome in the transplant recipient. Goals in the treatment of this clinical problem include: 1. Preserving coronary perfusion through maintenance of systemic blood pressure. 2. Optimizing RV preload. 3. Reducing RV afterload by decreasing pulmonary vascular resistance (PVR). 4. Limiting pulmonary vasoconstriction through ventilation with high inspired oxygen concentrations (100% Fio2), increased tidal volume and optimal positive end expiratory pressure ventilation. Inhaled nitric oxide is recommended before leaving the operating room in cases where the initial therapies have had little impact. Intra-aortic balloon counterpulsation is employed in patients with impaired left ventricular (LV) function and may be of benefit in patients with RV dysfunction resulting from ischemia, preservation injury or reperfusion injury. Optimal LV function reduces RV afterload and PVR. A proactive decision regarding RV assist device implantation is made before leaving the operating room and is highly dependent upon overall hemodynamics, size and function of the ventricles as seen on transesophageal echocardiography, renal function and surgical bleeding. Only through careful preoperative planning can this life-threatening condition be managed in the postoperative period.</description><subject>Alprostadil - therapeutic use</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cardiotonic Agents - therapeutic use</subject><subject>Epoprostenol - therapeutic use</subject><subject>Heart Transplantation - adverse effects</subject><subject>Heart Transplantation - physiology</subject><subject>Heart-Assist Devices</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - etiology</subject><subject>Hypertension, Pulmonary - therapy</subject><subject>Medical sciences</subject><subject>Milrinone - therapeutic use</subject><subject>Nitric Oxide - therapeutic use</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Risk Factors</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the heart</subject><subject>Vasodilator Agents - therapeutic use</subject><subject>Ventricular Dysfunction, Right - drug therapy</subject><subject>Ventricular Dysfunction, Right - etiology</subject><subject>Ventricular Dysfunction, Right - therapy</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhi3UCpaPn0DlSxEcUjx2HDsnhBDQSkg9FE4cLMee7LrKx9ZOVuq_x8uuyrGnkUbPO_PqIeQc2DdgUF3_YkrIAlitLhlcMSh1VYgDsgApdSFkrT6RxT_kiByn9JsxVmmoD8kRgNRCV2xBXp9XSHEzdpswLGlvB7vEHoeJji21bp6QxrBcTUUKHj1doY0TbW3o5og0DNTZ6IN1dIp2SOvO5mBEF9Yhn0in5HNru4Rn-3lCXh7un---F08_H3_c3T4VrlR8KoRyrhHASi5zeSZbWbaVk17J2tq84bypNS-lU7XwutFaQuMq0UouQDW-FifkYnd3Hcc_M6bJ9CE57HIdHOdkFHDOGN-Ccge6OKYUsTXrGHob_xpgZmvVvFs1W2WGgXm3akTOfdk_mJse_UdqrzEDX_eATc52bbbhQvrgShAK5LbAzY7DrGMTMJrksiqHPmRtk_Fj-E-VN_jIk2A</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Stobierska-Dzierzek, Bozena</creator><creator>Awad, Hamdy</creator><creator>Michler, Robert E</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011001</creationdate><title>The evolving management of acute right-sided heart failure in cardiac transplant recipients</title><author>Stobierska-Dzierzek, Bozena ; Awad, Hamdy ; Michler, Robert E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-37ccb31042515505f54f6c5d759aa15522b98245c793d8b8851bc63f52317bd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Alprostadil - therapeutic use</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cardiotonic Agents - therapeutic use</topic><topic>Epoprostenol - therapeutic use</topic><topic>Heart Transplantation - adverse effects</topic><topic>Heart Transplantation - physiology</topic><topic>Heart-Assist Devices</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - etiology</topic><topic>Hypertension, Pulmonary - therapy</topic><topic>Medical sciences</topic><topic>Milrinone - therapeutic use</topic><topic>Nitric Oxide - therapeutic use</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Risk Factors</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the heart</topic><topic>Vasodilator Agents - therapeutic use</topic><topic>Ventricular Dysfunction, Right - drug therapy</topic><topic>Ventricular Dysfunction, Right - etiology</topic><topic>Ventricular Dysfunction, Right - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stobierska-Dzierzek, Bozena</creatorcontrib><creatorcontrib>Awad, Hamdy</creatorcontrib><creatorcontrib>Michler, Robert E</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stobierska-Dzierzek, Bozena</au><au>Awad, Hamdy</au><au>Michler, Robert E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The evolving management of acute right-sided heart failure in cardiac transplant recipients</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>38</volume><issue>4</issue><spage>923</spage><epage>931</epage><pages>923-931</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>Avoidance of the clinical syndrome of acute right-sided heart failure after heart transplantation is, unfortunately, not possible. Clinical experience and the literature certainly suggest that a significant factor in the successful management of right ventricular (RV) failure is recipient selection. Moreover, threshold hemodynamic values beyond which RV failure is certain to occur and heart transplantation is contraindicated do not exist. Nor are there values below which RV failure is always avoidable. Acute RV failure will remain a difficult and ever-present clinical syndrome in the transplant recipient. Goals in the treatment of this clinical problem include: 1. Preserving coronary perfusion through maintenance of systemic blood pressure. 2. Optimizing RV preload. 3. Reducing RV afterload by decreasing pulmonary vascular resistance (PVR). 4. Limiting pulmonary vasoconstriction through ventilation with high inspired oxygen concentrations (100% Fio2), increased tidal volume and optimal positive end expiratory pressure ventilation. Inhaled nitric oxide is recommended before leaving the operating room in cases where the initial therapies have had little impact. Intra-aortic balloon counterpulsation is employed in patients with impaired left ventricular (LV) function and may be of benefit in patients with RV dysfunction resulting from ischemia, preservation injury or reperfusion injury. Optimal LV function reduces RV afterload and PVR. A proactive decision regarding RV assist device implantation is made before leaving the operating room and is highly dependent upon overall hemodynamics, size and function of the ventricles as seen on transesophageal echocardiography, renal function and surgical bleeding. Only through careful preoperative planning can this life-threatening condition be managed in the postoperative period.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11583860</pmid><doi>10.1016/S0735-1097(01)01486-3</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0735-1097 |
ispartof | Journal of the American College of Cardiology, 2001-10, Vol.38 (4), p.923-931 |
issn | 0735-1097 1558-3597 |
language | eng |
recordid | cdi_proquest_miscellaneous_71220029 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier); Alma/SFX Local Collection |
subjects | Alprostadil - therapeutic use Animals Biological and medical sciences Cardiotonic Agents - therapeutic use Epoprostenol - therapeutic use Heart Transplantation - adverse effects Heart Transplantation - physiology Heart-Assist Devices Hemodynamics Humans Hypertension, Pulmonary - etiology Hypertension, Pulmonary - therapy Medical sciences Milrinone - therapeutic use Nitric Oxide - therapeutic use Phosphodiesterase Inhibitors - therapeutic use Risk Factors Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the heart Vasodilator Agents - therapeutic use Ventricular Dysfunction, Right - drug therapy Ventricular Dysfunction, Right - etiology Ventricular Dysfunction, Right - therapy |
title | The evolving management of acute right-sided heart failure in cardiac transplant recipients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A12%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20evolving%20management%20of%20acute%20right-sided%20heart%20failure%20in%20cardiac%20transplant%20recipients&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Stobierska-Dzierzek,%20Bozena&rft.date=2001-10-01&rft.volume=38&rft.issue=4&rft.spage=923&rft.epage=931&rft.pages=923-931&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/S0735-1097(01)01486-3&rft_dat=%3Cproquest_cross%3E71220029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71220029&rft_id=info:pmid/11583860&rft_els_id=S0735109701014863&rfr_iscdi=true |